DDInter927 DDInter493
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.
Degarelix {u} (Compound) resembles {v} (Compound) Nafarelin
Degarelix {u} (Compound) resembles {v} (Compound) Cetrorelix
Degarelix {u} (Compound) treats {v} (Disease) prostate cancer
Degarelix {u} (Compound) binds {v} (Gene) GNRHR
Degarelix {u} (Compound) causes {v} (Side Effect) Urticaria
Degarelix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Degarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tamoxifen
Degarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Degarelix {u} may lead to a major life threatening interaction when taken with {v} Amiodarone
Degarelix {u} may lead to a major life threatening interaction when taken with {v} Ivabradine
Degarelix (Compound) resembles Nafarelin (Compound)
Degarelix (Compound) resembles Cetrorelix (Compound)
Degarelix (Compound) treats prostate cancer (Disease)
Degarelix (Compound) binds GNRHR (Gene)
Degarelix (Compound) causes Urticaria (Side Effect)
Degarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen
Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Degarelix may lead to a major life threatening interaction when taken with Amiodarone
Degarelix may lead to a major life threatening interaction when taken with Ivabradine